Intriguingly, this inhibitory effect of DCLK1-IN-1 on XRCC5 phosphorylation and COX2 expression was conserved across a broad range of cancer cell lines such as BT-474 (breast cancer), A549 (lung cancer), and PANC-1 (pancreas cancer), suggesting the versatility of the DCLK1/XRCC5/COX2 axis in many types of cancer (Figure S7). Here, XRCC5 is linked to breast carcinoma.